

**FORM 7**  
**MONTHLY PROGRESS REPORT**

Name of Listed Issuer: **MARAPHARM VENTURES INC. (Marapharm or the "Company")** (the "Issuer").

Trading Symbol: **MDM**

Number of Outstanding Listed Securities: **93,834,936**

Date: **December 5, 2017**

**Report on Business**

**1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

- *Marapharm closed the second tranche of the warrant private placement on November 7, 2017 and announced by News Release on November 8<sup>th</sup>, 2017 that the Company raised \$696,528. The proceeds will be utilized by Marapharm for development and corporate purposes. Each warrant will be offered for a consideration of 10 cents (CDN) per warrant for a total of gross proceeds of up to \$8 million dollars and are exercisable into one common share for the price of \$2.90 per share for a period of 3 years from the date of closing (the "warrants").*
- **California:** *The Company is proceeding with the development and licensing of two properties in California. In addition, the Company entered into an agreement to purchase, Green Leaf Wellness Inc., a dispensary located in Desert Hot Springs.*  
*In Washington renovations are proceeding as scheduled.*
- **Nevada:** *Good progress is being made in construction. The two 5,000sq' buildings have been erected and are undergoing tenant improvements, in preparation for cultivation and processing. Genetics have been started in the two onsite modular buildings.*
- **Washington:** *The Company has worked on designs that will enhance the value of the assets acquired, including plans for the purchase of new equipment and*

*building improvements. Insulation application is 75% complete. Plans for the next phase of renovations will be submitted to the County and the State.*

- **Canada:** Amendments are being made to our Health Canada application to comply with the new regulations (ACMPR), as well as adjusting its current application to include the processing of medical marijuana, appointment of new team members and possibly a new location.

**2. Provide a general overview and discussion of the activities of management.**

Brian Lovig - President - Continues to oversee funding and new acquisitions.

Linda Sampson - CEO - Continues to oversee all aspects of the Company's corporate business.

Corey Klassen - CFO - Continues to oversee project development.

Kurt Keating - Manager of Operations - Continues to oversee all aspects related to preparing for the operations of all locations.

**3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.**

*None to report this period.*

**4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.**

*No products or services have been discontinued.*

**5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.**

*No new business relationships have been entered into.*

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

*An Accounting contract with Nicolette Keith has been terminated.*

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

*The Company secured the acquisition of Green Leaf Wellness Inc., in Desert Hot Springs, California, a medical marijuana dispensary, by depositing, \$160,000 USD into escrow. The purchase price is \$1,600,000 USD.*

8. Describe the acquisition of new customers or loss of customers.

*Not applicable.*

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

*None to report this period.*

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

*There is no new hiring.*

11. Report on any labour disputes and resolutions of those disputes if applicable.

*There are no labour disputes.*

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

- *Marapharm was served with a notice of claim by Armadillo Resources Inc. for unpaid rent. The Company disputed the claim as no contract*

was ever entered into with Armadillo Resources Inc. for the payment of rent. A Settlement Conference in the Provincial Small Claims Court was held on August 30, 2017, the matter will proceed to trial on January 11, 2018. Upon the acquisition of new evidence, the Company has subsequently filed a counterclaim.

- The Company was named as a plaintiff in a case Between Pinto Ventures Ltd.(Pinto) and Christopher John Hunt (Hunt), regarding a private deal between "Pinto" and "Hunt" involving the Company's securities.

**13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**

*The Company continues to pay its bondholders interest from the date of the close of the first tranche as announced on May 8, 2017.*

**14. Provide details of any securities issued and options or warrants granted.**

*None to report this period.*

*(1) State aggregate proceeds and intended allocation of proceeds.*

Security	Number Issued	Details of Issuance	Use of Proceeds <sup>(1)</sup>
Warrant	6,967,282	.10c warrant convertible for up to three years, conversion rate \$2.90, warrant expires November 7, 2020.	The proceeds will be used for the development of the Washington and Nevada projects and for general corporate purposes.

**15. Provide details of any loans to or by Related Persons.**

*\$306,847.55 was repaid in full to the company on November 9<sup>th</sup>, 2017 by a related party due to a difference resulting from a transaction.*

**16. Provide details of any changes in directors, officers or committee members.**

*None to report this period.*

**17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**

**Nevada:** - the legalization and implementation of the recreational marijuana program.

**Washington:** - Washington State dismantled the medical marijuana initiative (I-692) in favour of the more regulated I-502. This removes the medical marijuana cultivators but allows medical dispensaries to dispense medical and recreational marijuana. Sales in Washington have broken records over the last several months.

**Canada:** - The Prime Minister of Canada has announced the legalization of recreational marijuana for July 2018.

**California:** - California is scheduled to move to legal recreational use in January, 2018.

### **Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were, is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated December 5, 2017

Linda Sampson  
Name of Director or Senior  
Officer

"Linda Sampson"

Signature

CEO

Official Capacity

<b>Issuer Details</b> Name of Issuer Marapharm Ventures Inc.	For Month End November 2017	Date of Report YY/MM/D 2017/12/05
Issuer Address 102-1561 Sutherland Avenue		
City/Province/Postal Code Kelowna, BC V1Y 5Y7	Issuer Fax No. ( )N/A	Issuer Telephone No. (778)583-4476
Contact Name Linda Sampson	Contact Position CEO	Contact Telephone No. (778) 583-4476
Contact Email Address Office@marapharm.com	Web Site Address www.marapharm.com	

---

**FORM 7 – MONTHLY PROGRESS REPORT**

December 5, 2017

Page 6